290 Binney Street
is a new commercial development consisting of 425,333 SF of lab and office space. The building is occupied by AstraZeneca and Alexion.
Image Credit: Aram Boghosian
The CRA welcomes another research headquarters to Kendall Square. The construction of the 290 Binney Street building was completed in summer 2026, and is now home to the North American headquarters of AstraZeneca and Alexion.
Construction of 290 Binney Street began in 2023 and progressed quickly thanks to an innovative method called “up-down construction,” where basement floors are built downward as excavation progresses and the upward structure starts simultaneously. The building’s exterior features trademark metal latticework that gives the project its distinct look. The development was made possible under the CRA’s Infill Concept Development Plan (IDCP), and CRA staff contributed design review and project feedback throughout the building’s development.
Review and Approval Documents:
290 Binney Street 2 Way Drive Aisle Presentation (August 27, 2024)
290 Binney Street Commercial (Approved April 19, 2022)
IDCP Amendment II Master Plan - (Approved January 14, 2022)
Massachusetts Environmental Policy Act - Certificate of Approval (November 2021)
This Project is Part of the IDCP (Infill Development Concept Plan). See other projects:
-
Project Partners:
BXP
Design Architect:
Pickard Chilton
Landscape Architect:
Lemon Brooke
General Contractor:
Turner Construction
Year Started:
2019 -
Joel Smith, ext 14, jsmith@cambridgeredevelopment.org
This Project In the News